Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $28.34 and traded as high as $28.35. Assembly Biosciences shares last traded at $28.24, with a volume of 118,749 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ASMB shares. Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Trading Up 7.1%

The firm has a market capitalization of $446.76 million, a PE ratio of -5.90 and a beta of 1.13. The stock’s 50 day moving average price is $32.13 and its two-hundred day moving average price is $28.34.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $7.46 million. Analysts expect that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Assembly Biosciences during the third quarter worth approximately $282,000. ADAR1 Capital Management LLC acquired a new stake in Assembly Biosciences during the third quarter worth approximately $485,000. Finally, Millennium Management LLC purchased a new stake in Assembly Biosciences in the 3rd quarter worth approximately $553,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.